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Bioﬁlms formed by Candida albicans, a human pathogen, are known to be resistant to differ-
ent  antifungal agents. Novel strategies to combat the bioﬁlm associated Candida infections
like  multiple drug therapy are being explored. In this study, potential of chloroquine to be
a  partner drug in combination with four antifungal agents, namely ﬂuconazole, voricona-
zole,  amphotericin B, and caspofungin, was explored against bioﬁlms of C. albicans. Activity
of  various concentrations of chloroquine in combination with a particular antifungal drug
was  analyzed in a checkerboard format. Growth of bioﬁlm in presence of drugs was analyzed
by  XTT-assay, in terms of relative metabolic activity compared to that of drug free control.
Results  obtained by XTT-metabolic assay were conﬁrmed by scanning electron microscopy.
The  interactions between chloroquine and four antifungal drugs were determined by calcu-
lating  fractional inhibitory concentration indices. Azole resistance in bioﬁlms was reverted
signiﬁcantly  (p < 0.05) in presence of 250 g/mL of chloroquine, which resulted in inhibition
of  bioﬁlms at very low concentrations of antifungal drugs. No signiﬁcant alteration in thesensitivity  of bioﬁlms to caspofungin and amphotericin B was evident in combination with
chloroquine.  This study for the ﬁrst time indicates that chloroquine potentiates anti-bioﬁlm
activity  of ﬂuconazole and voriconazole.
because of side effects due to toxicity; hence there is a need
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
bility of Candida albicans to exist in sessile community form
rovides  tolerance to stress conditions.1 Formation of commu-
ity  growth is initiated by surface induced gene expression.2
dhesion of cells to tissue surfaces or solid surface of pros-
heses  in the patient’s body activates cellular events leading
o  formation of bioﬁlms.3 Bioﬁlms are drug resistant growth
orms  which pose a serious threat to immunocompromised
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Este é um artigo Open Access sob a licençapatients.4,5 Resistance to various antifungal drugs showed
by  C. albicans bioﬁlms is considered as a multi-factorial
phenomenon involving different cellular mechanisms.6,7 No
single  antifungal antibiotic was found effective against bioﬁlm
related  C. albicans infections at low concentrations. Higher
concentrations of the antifungal drugs are not advisable
8nded MS 431606, India.
to  devise novel anti-bioﬁlm strategies.9 Combination of drugs
which  act on different cellular targets simultaneously may
offer  increased drug efﬁcacy and speciﬁcity.10,11 Chloroquine
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(CQ) has been extensively used against malaria for almost
seventy  years.12 CQ is believed to target polymerization of
ferriprotoporphyrine IX (heme moiety) which creates toxic
environment inside plasmodial parasite resulting into cell
death.13
Although CQ is used as a ﬁrst line drug against malaria
in  many  countries like Indonesia, India, Papua New Guinea,
Myanmar, Guyana and South America its use has been
suspended due to emergence of CQ-resistant strains of Plas-
modium  falciparum as well as P. vivax.14,15 Emerging resistance
to  CQ has posed a limitation on its antimalarial use; how-
ever,  efforts are being done to repurpose this molecule
for  novel therapeutic activities. For example, CQ has been
used  as an antiretroviral in clinical trials in HIV infected
patients with tumors.16 In a study by Sotelo et al., CQ
was  found effective in therapeutics against glioblastoma in
HIV patients.17 CQ was  found to possess antifungal activ-
ities  against fungal pathogens Cryptococcus neoformans and
Histoplasma  capsulatum.18,19 Surprisingly, its effects on the
most  common fungal pathogen C. albicans have not been
studied.  This study discusses effects of CQ on C. albicans
growth in planktonic and bioﬁlm forms. Efﬁcacy of CQ in
combination with four important antifungal drugs, namely
ﬂuconazole, voriconazole, amphotericin B, and caspofungin,
is  tested against planktonic cells, bioﬁlm development as well
as mature bioﬁlms of C. albicans.
Materials  and  methods
Cultures  and  antifungal  agents
A standard strain of C. albicans, ATCC 90028, was  obtained
from  the Institute of Microbial Technology (IMTECH), Chandi-
garh,  India. Culture was  maintained on yeast peptone dextrose
(YPD)  agar slants at 4 ◦C (all the media components were  pur-
chased  from HiMedia laboratories Pvt. Ltd. Mumbai, India).
Antifungal agents Fluconazole (FLC) (Forcan, Cipla Ltd., India),
Voriconazole  (VOR) (Vonaz, United Biotech Pvt. Ltd., India),
Caspofungin (CSP) (CancidasTM, Merck & Co. Inc., USA),
Amphotericin B (AmB) (Lyka Pharm. Pvt. Ltd., India), and
Chloroquine (CQ) (Lariago®, Ipca Laboratories Ltd., India) were
obtained  from local market.
Medium  and  culture  conditions
Activation of culture was  done by inoculating a single colony
from  YPD agar plate into 50 mL  YPD broth (yeast extract 1%,
peptone  2%, and dextrose 2%) in a 250 mL  conical ﬂask. The
ﬂasks  were  incubated at 30 ◦C at 100 rpm on an orbital shaking
incubator for 24 h. Cells were harvested by centrifugation at
2000  × g and washed thrice with 0.1 M phosphate buffer saline
(PBS),  pH 7.4. Final cell number was  adjusted to 1 × 107 cells/mL
and  used for experiments.
Susceptibility  of  planktonic  cells  to  antifungal  drugsThe susceptibility study was  carried out by the standard
broth micro dilution method as per CLSI guidelines. Var-
ious  concentrations of drugs were  prepared; FLC was  in 1 3;1  7(4):395–400
the  range 128–0.125 g/mL, while VOR was  between 8 g/mL
and  0.015 g/mL. Range of concentrations used for CSP and
AmB  were 4–0.007 g/mL. The concentrations of CQ were
in  the range 500–0 g/mL. All the drug concentrations were
prepared in RPMI-1640 medium pH 7.0 (with l-glutamine,
without sodium bicarbonate, buffered with 165 mM MOPS;
purchased from HiMedia laboratories Pvt. Ltd., Mumbai, India),
in  the wells of micro plates by double dilution. Wells with-
out  drug served as a control. Cells were added to each well
to  obtain density of 1 × 103 cells/mL. Plates were  incubated
at  35 ◦C for 48 h and absorbance was  read at 620 nm using
a  microplate reader (Multiskan EX, Thermo Electron Corp.,
USA).  The lowest concentration of the drugs which caused ﬁfty
percentage reduction in the absorbance compared to that of
control  was  considered as minimum inhibitory concentration
(MIC).7
Checkerboard  format  for  determination  of  FICI
Dilutions of individual drugs and their different combinations
were  prepared in a checkerboard format. A two dimensional
array of serial concentrations of test compounds was used for
preparation of dilutions of the drugs. 100 L of the cell suspen-
sion  was added to each well and the plates were  incubated
at  35 ◦C. Plates were read spectrophotometrically at 620 nm,
after  48 h of incubation. The FIC Indices were calculated using
following  equation:
∑
FIC = FICA + FICB, where FICA = (MIC of
drug  A in combination/MIC of drug A alone), FICB = (MIC of
drug  B in combination/MIC of drug B alone). When the value of∑
FIC ≤ 0.5 it is the synergism, and when
∑
FIC > 4 it is known
as  the antagonism. A
∑
FIC result of >0.5 but ≤4 is considered
as  indifference.20,21
Bioﬁlm  formation
Bioﬁlm formation was  carried using in vitro bioﬁlm model.7
Brieﬂy, 100 L of cell suspension (1 × 107 cells/mL in PBS) was
added  to wells of tissue culture grade polystyrene micro plates.
Plates  were incubated at 37 ◦C on an orbital shaker for 90 min
of  adhesion phase. All the wells were washed with sterile
PBS  to remove non-adhered cells. Two hundred l of RPMI-
1640  medium, pH 7.0, containing various concentrations of
the  drugs was  added to each well. The plates were  incubated
at  37 ◦C at 100 rpm in an orbital shaker for 48 h. Quanti-
tation of growth was  done by using XTT-metabolic assay,
where  the colored end product was  read spectrophotometri-
cally.
Bioﬁlm  quantitation  by  XTT  assay
Bioﬁlm formation was  quantitated using XTT [i.e.
2,3-bis (2-methoxy-4-nitro-sulfophenyl)-2H-tetrazolium-
5-carboxanilide] (Sigma–Aldrich, India) reduction assay.7
Brieﬂy, XTT solution was  prepared by mixing 1 mg/mL  XTT
salt  in PBS and stored at −20 ◦C. Prior to use, menadione solu-
tion  prepared in acetone (Sigma–Aldrich, India) was added
to  XTT to a ﬁnal concentration of 4 M. The wells containing
bioﬁlms were washed with PBS to remove non-adhered cells
and  100 L of XTT-menadione solution was  added to it. The
plates  were  incubated for 5 h in dark at 37 ◦C at 100 rpm.
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Table 1 – MICs of ﬁve antifungal drugs alone and in combination with 250 g/mL CQ for planktonic and bioﬁlm growth of
C. albicans.
Name of the drug Minimum inhibitory concentration (in g/mL)
Planktonic cells Bioﬁlm development Mature bioﬁlms
Antifungal
drug
Antifungal
drug + CQ
Antifungal
drug
Antifungal
drug + CQ
Antifungal
drug
Antifungal
drug + CQ
FLC 0.5 0.5 NAa (>128) 4 NAa (>128) 4
VOR 0.25 0.125 NA (>8) 0.25 NA (>8) 0.25
CSP 0.125 0.062 0.25 0.25 0.5 0.25
AmB 0.125 0.062 0.5 0.125 1 0.5
FLC, ﬂuconazole; VOR, voriconazole; CSP, caspofungin; AmB, amphotericin B; CQ, chloroquine.
a NA, Not achieved up to highest concentration tested. Comparison of MICs of the drugs alone and in combination with CQ indicates either
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(indifference or synergism in the combination.
ntensity of the colored formazan end product was  measured
t  450 nm using a micro plate reader. Wells without bioﬁlms
erved  as a blank.
icroscopic  analysis  of  bioﬁlms
ioﬁlms were  observed under an inverted light microscope
Metzer, India). Photographs were taken by a Labomed
icrophotography system (Labomed, Mumbai, India). For
canning  electron microscopy (SEM), samples were  ﬁxed in
.5%  glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), for
4  h at 4 ◦C. Samples were post-ﬁxed in 2% aqueous solution
f  osmium tetraoxide for 4 h, then dehydrated in a series of
raded  alcohols and ﬁnally dried to a critical drying point with
 Critical Point Dryer unit. The samples were mounted over
tubs,  and gold coating was  performed using an automated
old  coater (model JOEL JFC-1600) for 3 min. Photographs were
aken  under a scanning electron microscope (model JOEL-JSM
600).7
esults
usceptibility  of  planktonic  growth  of  C.  albicans  to
arious  antifungal  drugs  and  their  combinations  with
hloroquine
lanktonic growth of C. albicans was  susceptible to differ-
nt  antifungal drugs at varying concentrations. MICs of FLC,
OR,  AmB,  and CSP were  found at 0.5 g/mL, 0.25 g/mL,
.125 g/mL and 0.25 g/mL, respectively (Table 1). Chloro-
uine  did not show any signiﬁcant effect on growth of
.  albicans and MIC  was  observed at 1 mg/mL. No signiﬁ-
ant  decrease in MICs of two azoles, FLC and VOR could
e  observed when cells were  treated in combination with
arious  concentrations of CQ. FIC indices for combination
f  250 g/mL concentration of CQ with azole drugs were
ound  to be >0.5. Similar observations were noted for CQ-
mB  interactions indicating no signiﬁcant reduction in the
IC  of AmB.  Addition of CQ could not lower down the CSP
oncentration required to inhibit growth of C. albicans. It
as  evident with the FIC index of 0.74 for this combination
Table 1).CQ-azole  combination  inhibits  bioﬁlm  formation  by  C.
albicans
FLC and VOR alone were ineffective against bioﬁlm formation.
No  signiﬁcant inhibition of C. albicans bioﬁlm development
could be obtained even at high concentrations of FLC and
VOR,  i.e. 128 and 8 g/mL, respectively. This indicated resis-
tance  toward the azole drugs. After combination with CQ,
concentrations of FLC and VOR required to inhibit bioﬁlms
were  lowered down dramatically. Various CQ-FLC combina-
tions  were  found to effectively inhibit bioﬁlm development in
C. albicans at 2–8 g/mL. For example, addition of 250 g/mL of
CQ  resulted in inhibition of bioﬁlm development at 4 g/mL of
FLC.  Similarly, CQ-VOR was  also effective and MIC  of VOR for
formation  of C. albicans bioﬁlms was  achieved at 0.25 g/mL
(Fig.  1A and B). FIC indices for CQ-FLC and CQ-VOR combina-
tions  against bioﬁlm development were found to be 0.156 and
0.187,  respectively, indicating synergistic activity. Results of
bioﬁlm  inhibition analyzed by XTT metabolic assay were  con-
ﬁrmed  by light as well as electron microscopy. Control without
drug  exhibited typical bioﬁlm structure consisting of dense
network  of ﬁlamentous forms and yeast cells attached to the
solid  surface (Fig. 2A). Although cell density was  less, normal
bioﬁlms  were  observed in presence of CQ, FLC and VOR alone
(Fig.  2B, C and D, respectively). No bioﬁlm growth was  observed
in  presence of FLC-CQ combination (Fig. 2E). Similarly, VOR-
CQ  treatment resulted in inhibition of bioﬁlms and only few
yeast  cells were found adhered to the surface (Fig. 2F). The
MIC  of AmB  for bioﬁlm development was at 0.5 g/mL, which
was  fourfold more  than that of planktonic MIC. When com-
bined  with 250 g/mL of CQ the effective AmB concentration
was 0.5 g/mL. The FIC index of 1.126 for this combination
indicated indifference activity in combination. Similarly, com-
bination of CQ with CSP exhibited no change in the MIC  for C.
albicans  bioﬁlm development (Table 1). FIC index of 0.621 for
CQ-CSP  was  indicative of additive effect.
Combination  with  CQ  sensitizes  mature  bioﬁlms  of  C.
albicans  to  azole  drugsMature bioﬁlms of C. albicans were highly resistant toward
activity of FLC and VOR. MICs were  not achieved even at very
high  concentrations, i.e. 128 g/mL of FLC and 8 g/mL of VOR.
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Fig. 1 – Activity of FLC and VOR antifungal drugs alone and in combination with CQ, against bioﬁlm development and
mature bioﬁlms of C. albicans (ATCC 90028). Percentage of growth was  analyzed by comparing relative metabolic activity
(RMA) obtained through XTT metabolic assay. (A) FLC-CQ against bioﬁlm development; (B) VOR-CQ against bioﬁlm
Q agdevelopment; (C) FLC-CQ against mature bioﬁlms; (D) VOR-C
When 250 g/mL of CQ was  added to the mature bioﬁlms, MIC
of  FLC was  obtained at 4 g/mL. This indicated effective com-
bination,  with FIC index of 0.25. Combination of CQ with VOR
resulted  in inhibition of mature bioﬁlms at concentrations as
low as 0.25 g/mL (Fig. 1C and D). The FIC index for CQ-VOR
combination was  calculated to be 0.187. Although C. albicans
bioﬁlms  were  found sensitive to AmB  and CSP, it required high
concentrations. When combined with CQ, twofold decrease
in  the effective concentrations of AmB  and CSP was  observed
(Table  1). The FIC indices for CQ-AmB and CQ-CSP drug com-
binations  were  0.496 and 0.366, which are considered to exert
synergistic  effect.
Discussion
Infections associated with bioﬁlms of C. albicans is a serious
problem  in immune-compromised population.1 Novel strate-
gies  for prevention and treatment of drug resistant bioﬁlms
are  required urgently. Various reasons have been proposed
to  be responsible for the antifungal resistance of C. albicans
bioﬁlms.6 Factors like extracellular polymer, overexpression
of  drug efﬂux pumps may  contribute to the drug resistance.22
Combination of drugs with different mode of action may
inhibit  multiple cellular targets and hence would be a good
strategy  against bioﬁlms. Combinatorial approach against
planktonic form of C. albicans has been studied and was
found  promising; however, only limited studies are available
on  bioﬁlms.23 Our study is of signiﬁcance as CQ combination
with various antifungal drugs is studied in planktonic as wellainst mature bioﬁlms.
as  bioﬁlm growth forms. No signiﬁcant change in MICs of anti-
fungal  drugs for planktonic growth of C. albicans was  noted
in  presence of CQ, suggesting no synergistic activity against
planktonic growth. Bioﬁlm formation and mature bioﬁlms
were  found resistant to the azoles, FLC and VOR (Table 1).
While  higher concentrations of CSP and AmB  were  required
for  preventive activity against bioﬁlms than that of plank-
tonic  growth. Resistance to FLC and increased tolerance to
VOR  exhibited by early phase bioﬁlms was totally reverted
by  the addition of CQ and bioﬁlm formation became several
folds  more  sensitive to these drugs. Similarly, mature bioﬁlms
which  were  resistant to azoles were found to be susceptible
to  these drugs in presence of CQ. Results of the study suggest
that  CQ can be developed as a promising partner molecule for
combination therapy against bioﬁlm. Although very effective
with  FLC and VOR, presence of CQ did not have signiﬁcant
synergism with CSP and AmB.  No alteration in the sensitiv-
ity  of developing as well as mature bioﬁlms to CSP and AmB
was  evident in combination with CQ. Reasons behind syn-
ergistic  activity only with two azoles need to be elucidated.
Phase speciﬁc events are reported to be responsible for azole
resistance  in bioﬁlms of C. albicans. Activation of drug efﬂux
pumps  in early phases and low membrane ergosterol content
in  mature phases of bioﬁlms was  found to play a major role
in  ﬂuconazole resistance.6 Earlier workers have reported that
CQ  inhibits cholesterol synthesis in Wistar rats.24 In treat-
ment  of malaria, CQ binds to the haematin (a toxic by product
of  hemoglobin proteolysis containing iron as a center) and
prevents  its incorporation in to haemozoin. The free form of
haematin  may  interfere with the normal membrane functions
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Fig. 2 – Scanning electron micrographs of FLC and VOR antifungal drugs alone and in combination with CQ,  against bioﬁlm
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f parasite resulting in its inhibition.24 A study of Saccha-
omyces cerevisiae showed that CQ inhibited the yeast growth
y  iron deprivation.25 Similar effects of CQ in C. albicans may
otentiate  FLC and VOR against bioﬁlm growth form. However,
he  exact mechanism remains to be elucidated. In summary,
his  in vitro study gives insight into use of CQ-azole combi-
ation  against bioﬁlms in C. albicans. The antifungal drugs
LC  and VOR are commonly prescribed against candidiasis,
s  such reduction in their effective dosages after combination
ith  CQ may  be of wide interest. However, to conﬁrm the util-
ty  of these drug combinations in clinics, in vivo studies are
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